Regulatory & PolicyAstraZeneca is facing a pivotal review as the U.S. Food and Drug Administration (FDA) prepares to hold the first cancer advisory panel meeting in nine months. The committee will evaluate the applications for camizestrant, an oral selective estrogen receptor degrader (SERD) for breast cancer, and Truqap, an AKT inhibitor aimed at prostate cancer treatment. This meeting underscores the critical role that advisory panels play in guiding regulatory decisions for cutting-edge oncology drugs.
Sophia Reynolds·Mar 9, 2026
Regulatory & PolicyThe newly appointed federal autism advisory board's cancellation of its first public meeting since its overhaul raises questions about the committee's future public engagement and regulatory direction on autism-related policies and initiatives.
Sophia Reynolds·Mar 7, 2026 
Healthcare InvestmentThe breakdown in contract negotiations between Mount Sinai and Anthem Blue Cross Blue Shield highlights the broader challenges faced by payers and providers amid escalating healthcare costs and administrative complexities. This separation further underscores the critical need for innovative strategies to manage and control healthcare expenses effectively.
Sophia Reynolds·Mar 5, 2026 
Healthcare InvestmentThe latest infusion of venture capital into biotech reflects growing interest in novel therapies for inflammatory bowel diseases. Following promising Phase 2b results demonstrating sustained clinical remission, Teva’s project has attracted major backing to support further clinical development and potential market entry.
Sophia Reynolds·Mar 4, 2026 
Regulatory & PolicyIntellia Therapeutics faced a setback last October when the FDA paused its CRISPR gene therapy studies after a patient experienced life-threatening enzyme elevations leading to death. After a thorough investigation and safety evaluation, the FDA has now fully lifted the hold, allowing Intellia to proceed with its late-stage clinical programs, marking a significant milestone in CRISPR therapeutic development.
Sophia Reynolds·Mar 3, 2026 
Medical TechnologyHealth Gorilla, a health data aggregator, has filed a motion to dismiss a lawsuit brought by Epic Systems and several healthcare providers. The case centers on allegations regarding the inappropriate access to nearly 300,000 patient records and underscores the complexities in national health data sharing, governance, and regulatory frameworks.
Sophia Reynolds·Mar 2, 2026 
Regulatory & PolicyA probe into allegations against Vinay Prasad, Director of the FDA’s Center for Biologics Evaluation and Research (CBER), focuses on accusations of creating a hostile work environment. The investigation reflects broader questions about leadership accountability and workplace standards within the agency.
Sophia Reynolds·Feb 27, 2026 
Biotech InnovationThe collaboration between Novo Nordisk and Vivtex marks a promising development in the pursuit of innovative oral therapies for complex metabolic disorders such as obesity and diabetes. This initiative is poised to expand treatment options beyond the existing injectable drugs, potentially enhancing patient adherence and therapeutic outcomes.
Sophia Reynolds·Feb 25, 2026 
Biopharmaceutical IndustryThe recent price reduction by Novo Nordisk on its obesity drug portfolio prompts a nuanced discussion about whether this move truly benefits patients in terms of affordability and expanded access. This article delves into the market dynamics and potential implications for healthcare stakeholders.
Sophia Reynolds·Feb 24, 2026 
Biopharmaceutical IndustryThe oncology field faces significant challenges due to expensive drug waste. By employing data-driven approaches and better forecasting, stakeholders can optimize supply chain management and reduce financial losses, ultimately benefiting patients and payers alike.
Sophia Reynolds·Feb 24, 2026 
Biopharmaceutical IndustryThe lawsuit centers on allegations that Johnson & Johnson promoted its prostate cancer drug using flawed data, misrepresenting its effectiveness compared to Bayer’s competing treatments. This case highlights the intense competitive dynamics and the critical importance of accurate data in pharmaceutical marketing.
Sophia Reynolds·Feb 23, 2026 
Biopharmaceutical IndustryThe collaboration that began in 2022 on the cell therapy anito-cel has culminated in Gilead's acquisition of Arcellx, aiming to broaden its cancer treatment portfolio and provide patients with potentially safer and more effective options. This strategic move positions Gilead to compete more aggressively in the multiple myeloma market against established therapies.
Sophia Reynolds·Feb 23, 2026 